Top View
- A Case of Cervical Cancer
- (12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
- (INN) for Biological and Biotechnological Substances
- Mini Review MOLECULARLY TARGETING the PI3K-Akt-Mtor
- | Hao Hata Kata Tai Mit on a Man Taiwan Ta Material
- Molecular Classification of Gastric Cancer: Towards a Pathway- Driven Targeted Therapy
- Targeted Therapies
- Therapeutic Targets and New Directions for Antibodies Developed for Ovarian Cancer
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Signaling Pathways Involved in Colorectal Cancer Progression
- Peptide Mimotopes Recognized by Antibodies Cetuximab and Matuzumab Induce a Functionally Equivalent Anti-EGFR Immune Response
- The Example of Lung Cancer Perrine Créquit1,2†, Ludovic Trinquart1,2,3,4*†, Amélie Yavchitz1,2,3 and Philippe Ravaud1,2,3,4,5
- Riport Letöltése
- Supplementary Appendix
- Thyroid Cancer Stem-Like Cells: from Microenvironmental Niches to Therapeutic Strategies
- THESIS (Final Revision)
- Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine Axel Kleespies,1Ivan Ischenko,1Martin E
- Probody Drug Conjugates
- WO 2017/112829 Al 29 June 2017 (29.06.2017) W P O P C T
- New Molecularly Targeted Therapies for Lung Cancer
- (2006.01) C07d 413/14
- ( 12 ) Patent Application Publication
- EGFR and C-Met Inhibitors Are Effective in Reducing
- Monoclonal Antibodies: an Emerging Class of Therapeutics in Non Small Cell Lung Cancer
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- Targeting the Epidermal Growth Factor Receptor Pathway
- Oncompass Report NÉV Anonymous a Realtime Oncology Molecular Treatment Calculator Számításaival
- WO 2016/081384 Al 26 May 2016 (26.05.2016) P O P C T
- Cetuximab in Non-Small-Cell Lung Cancer
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- (INN) for Biological and Biotechnological Substances
- Vectibix AHM
- Second-Line Combination Therapies in Nonsmall Cell Lung Cancer Without Known Driver Mutations
- Determining the Role of Muc1 and Beta-Catenin on the Epidermal Growth Factor Receptor Signaling and Localization in Breast Cancer
- Truncated Epiderimal Growth Factor Receptor (Egfrt) for Transduced T Cell Selection
- Efficacy and Safety of Target Combined Chemotherapy In
- Influence of Antigen Mass on the Pharmacokinetics of Therapeutic
- Assessment of the Evolution of Cancer Treatment Therapies
- Characterizing and Engineering Antibodies Against the Epidermal Growth Factor Receptor
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- The Relative Efficacy and Safety of Targeted Agents Used In